Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Cataract surgery combined with trabecular micro bypass stent implantation in patients with open-angle glaucoma: 3 year follow-up

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Combined Cataract Surgery Techniques. Surgical Devices

Session Date/Time: Saturday 05/09/2015 | 08:30-10:30

Paper Time: 09:00

Venue: Main Auditorium

First Author: : G.Beiko CANADA

Co Author(s): :                        

Abstract Details

Purpose:

To determine the effectiveness of IOP control following combined cataract surgery and trabecular micro bypass stent implantation.

Setting:

The Niagara Health System, Ontario, Canada

Methods:

Retrospective analysis of the first 100 patients selected for trabecular micro bypass stent implantation surgery. The patients had visually significant cataracts and medically controlled open angle glaucoma. 6, 12, and 36 month data regarding number of topical medications and intraocular pressure was collected.

Results:

Of the 100 initial patients implanted, data was available on 49 at 3 years post-op. The average age at time of surgery was 78.286 +/- 6.877 yrs; 28.57 % were diabetic. The preop IOP was 16.837 +/- 3.243 mm Hg (range 10 - 23); there was no statically difference in IOP at 6 months (15.875 +/- 2.349 mm Hg (range 12 – 20); at 12 months 16.429 +/- 3.270 mm Hg (range 8 – 21), or at 36 months, 16.531 +/- 3.964 mm Hg (range 9 – 23). There was a statistically significant decrease in the number of topical glaucoma meds at 6 (P=0.001), 12 (P=0.002) and 36 months (P= 0.000).

Conclusions:

Trabecular micro bypass stent implantation at the time of cataract surgery offers an opportunity for glaucoma patients to be able to decrease their reliance on topical glaucoma medications.

Financial Interest:

One of the authors receives consulting fees, retainer, or contract payments from a competing company, One of the authors research is funded, fully or partially, by a competing company

Back to previous